ArticleBMC genomics2025
Machine learning assessment of zoonotic potential in avian influenza viruses using PB2 segment.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Viral Sentry AI-Automated zoonotic surveillance and drug repurposing agent.Biology methods & protocols · 2026Article
- Forecasting Influenza Epidemics and Pandemics in the Age of AI and Machine Learning.Reviews in medical virology · 2026Review
- A Novel Recombinant Chicken-Derived H6N8 Subtype Avian Influenza Virus Caused Disease in Chickens and Mice.Viruses · 2025Article
- Predicting host tropism in influenza a viruses: insights from multi-segment nucleotide signatures.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfluenza A virus (IAV) is a major global health threat, causing seasonal epidemics and occasional pandemics. Particularly, Influenza A viruses from avian species pose significant zoonotic threats, with PB2 adaptation serving as a critical first step in cross-species transmission. A comprehensive risk assessment framework based on PB2 sequences is necessary, which should encompass detailed analyses of specific residues and mutations while maintaining sufficient generality for application to non-PB2 segments.
resultsIn this study, we developed two complementary approaches: a regression-based model for accurately distinguishing among risk groups, and a SHAP-based risk assessment model for more meaningful risk analyses. For the regression-based risk models, we compared various methodologies, including tree ensemble methods, conventional regression models, and deep learning architectures. The optimized regression model, combined with SHAP value analysis, identified and ranked individual residues contributing to zoonotic potential. The SHAP-based risk model enabled intra-class analyses within the zoonotic risk assessment framework and quantified risk yields from specific mutations.
conclusionExperimental analyses demonstrated that the Random Forest regression model outperformed other models in most cases, and we validated the target value settings for risk regression through ablation studies. Our SHAP-based analysis identified key residues (271A, 627K, 591R, 588A, 292I, 684S, 684A, 81M, 199S, and 368Q) and mutations (T271A, Q368R/K, E627K, Q591R, A588T/I/V, and I292V/T) critical for zoonotic risk assessment. Using the SHAP-based risk assessment model, we found that influenza A viruses from Phasianidae showed elevated zoonotic risk scores compared to those from other avian species. Additionally, mutations I292V/T, Q368R, A588T/I, V598A/I/T, and E/V627K were identified as significant mutations in the Phasianidae. These PB2-focused quantitative methods provide a robust and generalizable framework for both rapid screening of avians' zoonotic potential and analytical quantification of risks associated with specific residues or mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.